Pain Information Center

News

FDA Approves Non-Opioid Treatment for Opioid Withdrawal

FDA Approves Non-Opioid Treatment for Opioid Withdrawal

Lucemyra is an oral selective alpha 2-adrenergic receptor agonist

Recommendations Developed for Managing Postpartum Pain

Impact of medications on mother-infant dyad should be considered, as many women breastfeed

First-of-Its-Kind Migraine Drug Receives FDA Approval

The efficacy of Aimovig was evaluated as a preventive treatment of episodic or chronic migraine in 3 randomized, double-blind, placebo-controlled studies: 2 studies in patients with episodic migraine (4-14 migraine days per month) and 1 study in patients with chronic migraine (≥15 headache days per month with ≥8 migraine days per month).

Opinion

Managing pain in primary care

A FNP reflects on his experiences working with pain management patients prescribed opioids.

Opioid use in middle-aged adults

Clinicians are in the unique position to educate and counsel middle-aged adults about their opioid use and influence strategies needed to provide effective pain control.

When patients need services that don't exist

It can be difficult to care for complex patients when they need services that do not exist.

Clinical Features

Managing Pediatric Migraine: Current Therapies and Future Directions

Managing Pediatric Migraine: Current Therapies and Future Directions

Migraine is highly prevalent in children and adolescents, affecting almost 10% of children between 5 and 15 years old and 30% of adolescents between 15 and 19 years old.

Assessing lidocaine efficacy for chronic pain management

Assessing lidocaine efficacy for chronic pain management

Intravenous, patch lidocaine might be effective in treating, preventing chronic pain.

Sign Up for Free e-newsletters